Two conditions, one drug: working to relieve chronic cough in IPF, and debilitating itch in prurigo nodularis with the opioid-receptor-targeting drug, HADUVIO

By way of an exquisite toggling of activity, HADUVIO stimulates one opioid receptor (kappa) and blocks the activity of another (mu) while avoiding the engagement of the third (delta). The  objective of this combination of receptor activity is to decrease chronic cough due to Idiopathic Pulmonary Fibrosis, or severe itch due to Prurigo Nodularis. Phase II data are available for both development programs,  which CEO Jennifer Good has proudly shared—along with a story of how Trevi got its name…